Abstract Purpose of Review Over the past decade, the pathogenic role of mutations in
isocitrate dehydrogenases (IDH) 1 and 2, affecting approximately 20% of patients with AML …

Recently, the discovery of biological and clinical properties of mutated isoforms 1 and 2
mutations of isocitrate dehydrogenases (IDH) 1 and 2, affecting approximately 20% of …

Acute myeloid leukemia (AML) is an aggressive disease with a poor prognosis. A large
percentage of patients succumb to this disease in spite of aggressive treatments with …

Isocitrate dehydrogenases (IDHs) are enzymes involved in multiple metabolic and
epigenetic cellular processes. Mutations in IDH1 or IDH2 are detected in approximately 20 …

Acute myeloid leukemia is a genetically heterogeneous hematologic malignancy;
approximately 20% of AML harbors a mutation in the isocitrate dehydrogenase (IDH) genes …

Abstract Purpose of Review Mutations in isocitrate dehydrogenase genes (IDH1 and IDH2)
are common in acute myeloid leukemia (AML), occurring in up to 30% of AML cases …

Advances in the treatment of acute myeloid leukemia (AML) over the last 40 years have
been limited. With an improved understanding of the pathophysiology of the disease, the …

The last decade has witnessed rapid advances in our understanding of molecular
leukemogenesis providing valuable insights from which to explore new therapeutic …

Mutations in isocitrate dehydrogenase isoform (IDH) 1 and 2 occur in approximately 25% of
patients with acute myeloid leukemia (AML). These mutations lead to a block in myeloid …

Mutations in the nicotinamide adenine dinucleotide phosphate+–dependent isocitrate
dehydrogenase gene 2 (IDH2) have recently been found in patients with acute myeloid …